Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPP 593

Drug Profile

HPP 593

Alternative Names: HPP593; REN-001 - Reneo Pharmaceuticals

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer High Point Pharmaceuticals; Reneo Pharmaceuticals; vTv Therapeutics LLC
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn error metabolic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inborn error metabolic disorders; Mitochondrial myopathies
  • Discontinued Diabetes mellitus; Dyslipidaemias; Muscle fatigue

Most Recent Events

  • 20 Sep 2019 HPP 593 receives Orphan Drug status for Inborn error metabolic disorders (Fatty acid oxidation disorders) in USA
  • 30 Aug 2019 Reneo Pharmaceuticals plans clinical trials for Inborn error metabolic disorders (Fatty acid oxidation disorders)
  • 10 May 2019 Reneo Pharmaceuticals initiates a phase I trial in Mitochondrial myopathies (In adolescents, In adults, In the elderly) in United Kingdom (PO) (NCT03862846)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top